Lanean...
Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials
Historically, androgen-deprivation therapy has been the cornerstone for treatment of metastatic prostate cancer. Unfortunately, nearly majority patients with prostate cancer transition to the refractory state of castration-resistant prostate cancer (CRPC). Newer therapeutic agents are needed for tre...
Gorde:
| Argitaratua izan da: | Ther Adv Urol |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
SAGE Publications
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4647138/ https://ncbi.nlm.nih.gov/pubmed/26622323 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287215597637 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|